EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Serving on an FDA Advisory Committee: One Member’s Point of View
Editorial Archive

Serving on an FDA Advisory Committee: One Member’s Point of View

The Federal Food, Drug, and Cosmetic Act (FD&C Act) is a federal law enacted by Congress. Along with other federal laws, it establishes the legal framework within...
Continue Reading →
Risk-based Quality Management: Improving Trials Data through Minimalism
Editorial Archive

Risk-based Quality Management: Improving Trials Data through Minimalism

There is no doubt about the importance of maintaining quality standards throughout clinical research processes, but in recent years the regulatory bodies have begun t...
Continue Reading →
How Emerging Companies Can Make Being Small a Strategic Advantage
Editorial Archive

How Emerging Companies Can Make Being Small a Strategic Advantage

Small- to mid-sized (aka “emerging”) firms bring fewer resources to bear on the same drug development problems as large pharmaceutical companies. All developers face ...
Continue Reading →
Drug Development in Systemic Lupus Erythematosus – Can it be Successful?
Editorial Archive

Drug Development in Systemic Lupus Erythematosus – Can it be Successful?

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes the immune system to produce several types of antibodies, particularly against cell nuclei. Th...
Continue Reading →
Boldly Going Where Few Have Gone before: Key Considerations for ‘Siteless’ Clinical Trials
Editorial Archive

Boldly Going Where Few Have Gone before: Key Considerations for ‘Siteless’ Clinical Trials

Advancements in technology are impacting many aspects of clinical research, opening doors to innovative study designs and clinical operations that may not have been p...
Continue Reading →
Catalyst: 12th January 2026
Quotient